Celldex Therapeutics (CLDX) EBT (2016 - 2025)
Historic EBT for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$67.0 million.
- Celldex Therapeutics' EBT fell 5917.0% to -$67.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.5 million, marking a year-over-year decrease of 4572.71%. This contributed to the annual value of -$157.9 million for FY2024, which is 1162.0% down from last year.
- Per Celldex Therapeutics' latest filing, its EBT stood at -$67.0 million for Q3 2025, which was down 5917.0% from -$56.6 million recorded in Q2 2025.
- In the past 5 years, Celldex Therapeutics' EBT ranged from a high of -$13.4 million in Q2 2021 and a low of -$67.0 million during Q3 2025
- Its 5-year average for EBT is -$34.7 million, with a median of -$32.8 million in 2024.
- Per our database at Business Quant, Celldex Therapeutics' EBT tumbled by 16922.9% in 2022 and then soared by 1528.16% in 2023.
- Celldex Therapeutics' EBT (Quarter) stood at -$20.1 million in 2021, then crashed by 31.46% to -$26.5 million in 2022, then tumbled by 63.5% to -$43.3 million in 2023, then fell by 8.74% to -$47.1 million in 2024, then crashed by 42.37% to -$67.0 million in 2025.
- Its last three reported values are -$67.0 million in Q3 2025, -$56.6 million for Q2 2025, and -$53.8 million during Q1 2025.